Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04305041
Title Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | FRA | AUS

Facility Status City State Zip Country Details
The Angeles Clinic and Research Institute ( Site 1009) Los Angeles California 90025 United States Details
UCLA Hematology & Oncology ( Site 1004) Los Angeles California 90095 United States Details
Providence Saint John's Health Center ( Site 1010) Santa Monica California 90404 United States Details
University of Colorado, Anschutz Cancer Pavilion ( Site 1012) Aurora Colorado 80045 United States Details
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 1022) Baltimore Maryland 21287 United States Details
NYU Clinical Cancer Center ( Site 1002) New York New York 10016 United States Details
Duke Cancer Institute ( Site 1005) Durham North Carolina 27710 United States Details
Martha Morehouse Tower ( Site 1020) Columbus Ohio 43221 United States Details
Oregon Health & Science University ( Site 1013) Portland Oregon 97239 United States Details
University of Pennsylvania Abramson Cancer Center ( Site 1008) Philadelphia Pennsylvania 19104 United States Details
West Cancer Center - East Campus ( Site 1014) Germantown Tennessee 38138 United States Details
University of Texas MD Anderson Cancer Center ( Site 1006) Houston Texas 77030 United States Details
Inova Schar Cancer Institute ( Site 1011) Fairfax Virginia 22031 United States Details
Calvary Mater Newcastle-Medical Oncology ( Site 1404) Waratah New South Wales 2298 Australia Details
Melanoma Institute Australia ( Site 1402) Wollstonecraft New South Wales 2065 Australia Details
Tasman Oncology Research Pty Ltd ( Site 1403) Southport Queensland 4215 Australia Details
Fiona Stanley Hospital ( Site 1401) Murdoch Western Australia 6150 Australia Details
Hopital La Timone ( Site 1103) Marseille Bouches-du-Rhone 13005 France Details
Hopital Saint Andre ( Site 1108) Bordeaux Gironde 33075 France Details
Institut Claudius Regaud ( Site 1105) Toulouse cedex 9 Haute-Garonne 31059 France Details
Gustave Roussy ( Site 1101) Villejuif Ile-de-France 94800 France Details
Centre Hospitalier Lyon Sud ( Site 1102) Pierre Benite Rhone 69495 France Details
A.P.H. Paris, Hopital Saint Louis ( Site 1107) Paris 75010 France Details
HaEmek Medical Center ( Site 1703) Afula 1834111 Israel Details
Rambam Health Care Campus-Oncology ( Site 1704) Haifa 3109601 Israel Details
Hadassah Ein Karem Jerusalem ( Site 1702) Jerusalem 9112001 Israel Details
Chaim Sheba Medical Center ( Site 1701) Ramat Gan 5265601 Israel Details
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1399) Milano 20133 Italy Details
Istituto Europeo di Oncologia ( Site 1301) Milano 20141 Italy Details
Istituto Nazionale Tumori Fondazione Pascale ( Site 1302) Napoli 80131 Italy Details
Istituto Oncologico Veneto IRCCS ( Site 1355) Padova 35128 Italy Details
Policlinico Le Scotte - A.O. Senese ( Site 1377) Siena 53100 Italy Details
Hôpitaux Universitaires de Genève (HUG)-Oncology ( Site 1603) Genève Geneve 1211 Switzerland Details
CHUV Centre Hospitalier Universitaire Vaudois ( Site 1602) Lausanne Vaud 1011 Switzerland Details
Universitaetsspital Zuerich ( Site 1601) Zuerich Flughafen Zurich 8058 Switzerland Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field